Table 2 Results of the different immunohistochemistry stainings in relation to survival
From: Evaluation of immunophenotype in diffuse large B-cell lymphoma and its impact on prognosis
Antibody | N | % | EFS 5 year | P-value | OS 5-year | P-value |
|---|---|---|---|---|---|---|
bcl-6 pos. | 78 | 48 | 67 | 0.000001 | 64 | 0.00003 |
bcl-6 neg. | 83 | 56 | 27 | 28 | ||
Missing | 0 | |||||
CD10 pos. | 56 | 35 | 64 | 0.007 | 57 | 0.04 |
CD10 neg. | 103 | 64 | 38 | 40 | ||
Missing | 2 | 1 | ||||
bcl-2 pos. | 89 | 55 | 37 | 0.0006 | 39 | 0.03 |
bcl-2 neg. | 67 | 42 | 58 | 54 | ||
Missing | 5 | 3 | ||||
IRF-4 pos. | 51 | 32 | 44 | 0.9 | 44 | 0.7 |
IRF-4 neg. | 101 | 63 | 46 | 44 | ||
Missing | 9 | 5 | ||||
Two-marker model | ||||||
Germinal center | 40 | 25 | 68 | 0.007 | 67 | 0.009 |
Nongerminal center | 119 | 74 | 40 | 40 | ||
Missing | 2 | 1 | ||||
Three-marker model | ||||||
Germinal center | 82 | 51 | 66 | 0.00001 | 58 | 0.002 |
Nongerminal center | 75 | 47 | 24 | 32 | ||
Missing | 4 | 2 | ||||
